PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Macroscopic fluorescence lifetime FRET imaging (MFLI-FRET) presents a much-needed analytical tool to non-invasively quantify drug-receptor engagement in tumors and other organs in preclinical studies. We demonstrate the specificity and sensitivity of MFLI-FRET for direct and robust measurement of trastuzumab-HER2 target engagement in various types of breast and ovarian cancer tumor xenograft models. Simultaneous metabolic imaging with IRDye 800 CW 2-DG reveals that intracellular delivery of drug is associated with 2-DG lifetime and likely reflects tumors’ microenvironment and perfusion state.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Alena Rudkouskaya, Jason T. Smith, Xavier R. Intes, Margarida Barroso, "Multiplexing drug-target engagement and metabolic imaging in HER2-positive tumor xenograft models," Proc. SPIE PC11938, Visualizing and Quantifying Drug Distribution in Tissue VI, PC1193809 (7 March 2022); https://doi.org/10.1117/12.2607308